June 14 (Reuters) - Resapp Health Ltd (RAP) :
- INCREASED SCHEME CONSIDERATION FROM PFIZER
- INCREASE SCHEME CONSIDERATION TO A$0.207 PER SHARE FROM A$0.115 PER SHARE IN CASH
- CO, PFIZER AGREED TO INCREASE CONSIDERATION TO A$0.146/SHARE IN CASH IF CONFIRMATORY DATA READOUT CONDITION NOT SATISFIED
- BOARD UNANIMOUSLY RECOMMENDS THAT RESAPP SHAREHOLDERS VOTE IN FAVOUR OF REVISED SCHEME
- WILL INCREASE SCHEME CONSIDERATION TO A$0.207 PER SHARE IN CASH, IF CONFIRMATORY DATA READOUT CONDITION IS SATISFIED
News: RAP Resapp Health Announces Increased Scheme Consideration From Pfizer
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)